About this trial
Thrombocytopenia is a clinical problem defined by a platelet count lower than 150×10⁹/L. It can be linked to various pathologies of central origin, such as decreased platelet production in the bone marrow, or peripheral origin with increased platelet destruction through autoimmune mechanisms, increased splenic sequestration, or excessive platelet consumption. Significant fatigue is often reported in association with thrombocytopenia, but its underlying pathophysiology remains unclear. One hypothesis is the role played by neurotrophic factors contained in platelets and released into the circulation following their activation, in particular the Brain-Derived Neurotrophic Factor (BDNF), which promotes the survival, growth, differentiation, and plasticity of neurons in both the central and peripheral nervous systems. Consequently, BDNF plays a key role in long-term memory, intellectual abilities, and neuroprotection.
In this context, this project aims to confirm whether platelet-origin neurotrophic biomarkers could explain the fatigue experienced by thrombocytopenic patients and whether it depends on the etiology of the thrombocytopenia.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with constitutional or autoimmune (chronic or persistent ITP with last treatment administration ≥ 3 weeks) thrombocytopenia (platelet count < 150×109/L) already diagnosed
patient not being treated and not receiving serotonin reuptake inhibitor (SSRI) or norepinephrine (SNRI) or antithrombotic treatments (antiplatelet or anticoagulant) in the 10 days prior to inclusion
affiliation to social security (beneficiary or assignee)
patient followed in consultation in one of the recruiting haematology departments
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
blood sampling
Biological/Vaccine3 blood tubes will be taken during a standard check-up
self-administrated questionaires
Other intervention4 self administrated questionaires and scales at the inclusion
Treatment groups
Trial outcomes
Primary outcomes
Blood BDNF levels in thrombocytopenic adult and pediatric patients
Measurement of BDNF levels in thrombocytopenic patients Adults and children with excessive fatigue
Fatigue questionnaire scores for adult and pediatric patients
Fatigue questionnaire scores for adult and pediatric patients with excessive fatigue
BDNF blood level in Healthy volunteers
Measurement of BDNF blood level in Healthy volunteers
Secondary outcomes
Measurement of pro-BDNF blood level in thrombopenic adult and pediatric patients
measurement of p75NTR blood level in thrombopenic adult and pediatric patients
measurement of TrkB blood level in thrombopenic adult and pediatric patients
measurement of MMP9 blood level in thrombopenic adult and pediatric patients
Sponsors and contacts
Click on the lead sponsor to view all of their trials.